[go: up one dir, main page]

PE20020225A1 - Composiciones farmaceuticas de farmacos poco solubles - Google Patents

Composiciones farmaceuticas de farmacos poco solubles

Info

Publication number
PE20020225A1
PE20020225A1 PE2001000321A PE2001000321A PE20020225A1 PE 20020225 A1 PE20020225 A1 PE 20020225A1 PE 2001000321 A PE2001000321 A PE 2001000321A PE 2001000321 A PE2001000321 A PE 2001000321A PE 20020225 A1 PE20020225 A1 PE 20020225A1
Authority
PE
Peru
Prior art keywords
solid
solubilizer
refers
composition
fatty acid
Prior art date
Application number
PE2001000321A
Other languages
English (en)
Inventor
Barbara Haeberlin
Barbara Luckel
Michael Abuhl
Armin Meinzer
Olivier Lambert
Laurent Marchal
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20020225A1 publication Critical patent/PE20020225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION EN FORMA SOLIDA QUE COMPRENDE FARMACO POCO SOLUBLE EN AGUA COMO CICLOSPORINA O UN MACROLIDO COMO FK 506; UN COMPONENTE SOLUBILIZANTE COMO ACIDO GRASO DE GLICERILO, PROPILENGLICOL, ALCOHOL GRASO; UN TENSIOACTIVO SEMISOLIDO O SOLIDO A TEMPERATURA AMBIENTE COMO ACEITE DE RICINO HIDROGENADO POLIETOXILADO, ESTER DE ACIDO GRASO DE POLIOXIETILENO, COPOLIMERO DE POLIOXIETILENO-POLIOXIPROPILENO, ENTRE OTROS; ADEMAS COMPRENDE UN VEHICULO COMO MALTODEXTRINA, LACTOSA, GOMA ARABIGA, GELATINA; SIENDO LA PROPORCION DEL TENSIOACTIVO AL SOLUBILIZANTE DE 0,3-4 A 1; QUE SE CARACTERIZA POR QUE i)AL DILUIRSE CON UN MEDIO ACUOSO FORMA UNA EMULSION, MICROEMULSION, SISTEMA DE PARTICULAS; ii)EL FARMACO DISUELTO EN EL SOLUBILIZANTE SE ENCAPSULA EN UNA MATRIZ POLIMERICA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE CONDICIONES AUTOINMUNES, INFLAMATORIAS, RECHAZO DE TRASPLANTES, RESISTENCIA A MULTIPLES FARMACOS
PE2001000321A 2000-04-10 2001-04-06 Composiciones farmaceuticas de farmacos poco solubles PE20020225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008785.8A GB0008785D0 (en) 2000-04-10 2000-04-10 Organic compounds

Publications (1)

Publication Number Publication Date
PE20020225A1 true PE20020225A1 (es) 2002-04-15

Family

ID=9889585

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000321A PE20020225A1 (es) 2000-04-10 2001-04-06 Composiciones farmaceuticas de farmacos poco solubles

Country Status (12)

Country Link
US (3) US20030133984A1 (es)
EP (2) EP1272163A2 (es)
JP (1) JP2003530340A (es)
CN (2) CN100431600C (es)
AU (1) AU2001250420A1 (es)
BR (1) BR0109931A (es)
CA (1) CA2404368C (es)
FR (1) FR2807658A1 (es)
GB (1) GB0008785D0 (es)
IT (1) ITMI20010748A1 (es)
PE (1) PE20020225A1 (es)
WO (1) WO2001076561A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
AU2003205543A1 (en) * 2003-01-14 2004-08-10 Lifecycle Pharma A/S Dry dispersions
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
HUE039643T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
CN101199836B (zh) * 2007-11-07 2011-03-30 安徽省药物研究所 一种阶段释放型环孢素a固体微乳制剂及其微乳固化方法
CU23892B1 (es) * 2007-12-07 2013-04-19 Ct De Investigación Y Desarrollo De Medicamentos Cidem Composición farmacéutica microencapsulada de ciclosporina a
HRP20140097T1 (hr) * 2008-11-21 2014-03-14 Boehringer Ingelheim International Gmbh Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu
SG177569A1 (en) 2009-07-07 2012-03-29 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
US20110105387A1 (en) * 2009-09-19 2011-05-05 Nian Wu Method of treatment with rapamycin
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
KR20180058659A (ko) 2015-05-20 2018-06-01 노파르티스 아게 에베롤리무스와 닥톨리십의 약제학적 병용물
ITUA20164228A1 (it) * 2016-06-09 2017-12-09 Labomar S R L Formulazione a matrice grassa auto-emulsionante e gastro-resistente e relativo metodo di preparazione
TW201825090A (zh) 2016-11-23 2018-07-16 瑞士商諾華公司 增強免疫反應之方法
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
WO2025153584A1 (en) * 2024-01-17 2025-07-24 Basf Se Solid self-emulsifying dosage form

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
US3244592A (en) 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
CA1326995C (en) * 1988-01-29 1994-02-15 Kozo Kurihara Cyclosporin compositions
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
EP0427680B1 (en) 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
ATE219356T1 (de) * 1990-11-06 2002-07-15 Nippon Shinyaku Co Ltd Lyophilisierte zubereitung sowie deren herstellung
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
ES2137516T3 (es) * 1994-06-01 1999-12-16 Yuhan Corp Composicion a base de ciclosporina y su procedimiento de fabricacion.
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
WO1999027946A1 (en) * 1997-12-02 1999-06-10 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP4815053B2 (ja) * 1998-08-13 2011-11-16 シーマ・ラブス、インコーポレイテッド 経口投与の固形投与形態物としてのマイクロエマルション
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU1043201A (en) * 1999-11-02 2001-05-14 Cipla Limited Cyclosporin formulation
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition

Also Published As

Publication number Publication date
US20030133984A1 (en) 2003-07-17
JP2003530340A (ja) 2003-10-14
ITMI20010748A0 (it) 2001-04-06
CN100431600C (zh) 2008-11-12
EP1767193A2 (en) 2007-03-28
CN1422149A (zh) 2003-06-04
CA2404368C (en) 2011-02-01
BR0109931A (pt) 2003-05-27
US20060134203A1 (en) 2006-06-22
CA2404368A1 (en) 2001-10-18
EP1767193A3 (en) 2009-01-28
GB0008785D0 (en) 2000-05-31
EP1272163A2 (en) 2003-01-08
FR2807658A1 (fr) 2001-10-19
CN1679916A (zh) 2005-10-12
AU2001250420A1 (en) 2001-10-23
ITMI20010748A1 (it) 2002-10-06
CN1231208C (zh) 2005-12-14
WO2001076561A2 (en) 2001-10-18
WO2001076561A3 (en) 2002-02-21
US20100215734A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
PE20020225A1 (es) Composiciones farmaceuticas de farmacos poco solubles
AU2010305404B2 (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
US6140374A (en) Propofol composition
KR20110067115A (ko) 피부 또는 질 점막에 적용하기 위한 변형된 방출 에멀젼
JP2960867B2 (ja) 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法
KR101003514B1 (ko) 안용 약물 전달을 위한 생침식성 필름
AR032497A1 (es) Limpiador antimicrobiano acido para superficies duras
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
CN106794126A (zh) 局部配制品
FR2761265A1 (fr) Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
PE20000272A1 (es) Formulaciones farmaceuticas de epotilonas
KR20090053797A (ko) 사이클로스포린 조성물
RU2010121989A (ru) Композиция для местного введения
US9138402B2 (en) Aripiprazole compositions and methods for its transdermal delivery
PE20010636A1 (es) Composiciones de agentes activos poco solubles como ciclosporina, paclitaxel o nifedipina para administracion oral o topica
UA79766C2 (en) Pharmaceutical formulation comprising cyclosporin and use thereof
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PT1171100E (pt) Composicao farmaceutica solubilizada para administracao parenteral
FR2598320A1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
CN107753419B (zh) 他克莫司外用制剂
CZ300213B6 (cs) Farmaceutická kompozice ve forme ocních kapek, zpusob její prípravy a použití azithromycinu
WO1999004790A1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
CN116916910A (zh) 渗透性冷冻保护剂及其制备和使用方法
BE1000535A4 (fr) Composition pharmaceutique injectable a base d'amoxicilline.
JP6067399B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
FD Application declared void or lapsed